Exploring drug sensitivity guided individualized treatment in pediatric spindle cell/sclerosing rhabdomyosarcoma.
In a retrospective cohort of 14 children with spindle cell/sclerosing rhabdomyosarcoma, drug-sensitivity testing was feasible in all patients, identified uniform platinum sensitivity, and guided 13 patients with stable or progressive disease after VAC to platinum-containing regimens, after which all 13 had an objective response.
Open original publication →What the AI sees
In a retrospective cohort of 14 children with spindle cell/sclerosing rhabdomyosarcoma, drug-sensitivity testing was feasible in all patients, identified uniform platinum sensitivity, and guided 13 patients with stable or progressive disease after VAC to platinum-containing regimens, after which all 13 had an objective response.
Research significance
The reported evidence supports the feasibility of assay-guided treatment selection and an association between predicted platinum sensitivity and subsequent response; it remains an unproven hypothesis that this strategy improves survival or performs better than empiric platinum treatment.
Source abstract
PURPOSE: Spindle cell and sclerosing rhabdomyosarcoma (sRMS/scRMS) are rare variants accounting for 5%-10% of all RMS cases. This study aimed to evaluate the feasibility of using drug sensitivity assay to guide real time treatment decisions in children with sRMS/scRMS. METHODS: We retrospectively analyzed 14 consecutive patients diagnosed with sRMS/scRMS between January 2020 and December 2024. All patients initially received two cycles of VAC (vincristine/dactinomycin/cyclophosphamide). If the tumor response is stable or progressive, subsequent treatment is tailored based on drug sensitivity assay. The primary endpoint was feasibility of drug sensitivity assay guided decision making. Secondary endpoints included objective response rate (ORR), PFS, and OS. RESULTS: Drug sensitivity assay revealed uniform platinum sensitivity across all patients. After two cycles of VAC, 13 of 14 patients exhibited either stable or progressive disease, suggesting limited efficacy of the VAC regimen in this cohort. These 13 patients were subsequently transitioned to a platinum containing regimen guided by drug sensitivity assay, following which an objective response was observed in all cases. The 5-year PFS and OS were 36.92% (95% CI, 11.82-61.33) and 53.85% (95% CI, 31.70-82.93), respectively. Compared with the historical median survival of 9 months for relapsed/refractory RMS, the outcomes in our cohort appeared to be somewhat longer, suggesting a potential clinical benefit. The approach proved to be feasible in all 14 patients. CONCLUSION: Our findings suggest that drug sensitivity assay may represent a feasible and potentially useful tool for informing real time treatment decisions in children with sRMS/scRMS. The incorporation of such testing into the therapeutic algorithm for this chemotherapy resistant sarcoma variant may offer a means to individualize treatment and possibly improve prognostic outcomes. However, given the exploratory nature and limited sample size of this study, these observations should be interpreted with caution, and larger prospective studies are needed to confirm their validity.